Physicians' Academy for Cardiovascular Education

Tackling residual risk beyond LDL-c therapy: The emerging role of EPA & triglycerides

Meeting report with presentation slides, videos and online CME of a PACE-CME symposium held during ESC 2021, The Digital Experience.

Integrating EPA-based therapy in the management of residual CV risk

10' education - Nov. 1, 2021 - Prof. Ph. Gabriel Steg, MD - Online CME
What is the role of icosapent ethyl in lowering residual CV risk? Prof. Steg answers this question by presenting observations from trials with EPA-based therapies.

What is the role of icosapent ethyl in lowering residual CV risk? Prof. Steg answers this question by presenting observations from trials with EPA-based therapies.

E-learning Tackling residual risk beyond LDL-c therapy: The emerging role of EPA & triglycerides

Accredited e-Learning

Online-CME - This course consists of 3 parts.
This course consists of 3 parts.

Many questions remain on the subject of triglycerides, EPA-based therapies and CV outcomes. Three discussants attempt to unravel the mysteries in this field.

What is the evidence of EPA-based therapy for CV prevention?

10' education - Oct. 12, 2021 - Prof. Lale Tokgözoğlu, MD - Online CME
Which formulation of omega-3 PUFAs should be used, and to whom and when should omega-3 PUFAs be prescribed? Prof. Lale Tokgözoğlu provides an overview of trials with omega-3 PUFAs and CV outcomes.

Which formulation of omega-3 PUFAs should be used, and to whom and when should omega-3 PUFAs be prescribed? Prof. Lale Tokgözoğlu provides an overview of trials with omega-3 PUFAs and CV outcomes.

Unravelling the triglyceride story

10' education - Sep. 21, 2021 - Prof. Peter Libby, MD - Online CME
What is the relationship between triglyceride-rich lipoproteins and CV risk? And what is the role of lipoprotein lipase in the metabolism of triglyceride-rich lipoproteins? Peter Libby answers these and other questions in this video.

What is the relationship between triglyceride-rich lipoproteins and CV risk? And what is the role of lipoprotein lipase in the metabolism of triglyceride-rich lipoproteins? Peter Libby answers these and other questions in this video.

Slides: Integrating EPA based therapy in the management of residual CV risk

Slides (presentation) - Sep. 13, 2021 - Prof. Ph. Gabriel Steg, MD - Paris, France - CME symposium held during ESC Congress 2021
This lecture by Prof. Ph. Gabriel Steg was part of a EBAC-accredited symposium

Slides as educational service to PACE members and meeting participants.

Slides: EPA based therapy in CAD: What do we know?

Slides (presentation) - Sep. 13, 2021 - Prof. Lale Tokgözoğlu, MD - Ankara, Turkey - CME symposium held during ESC Congress 2021
This lecture by Prof. Lale Tokgözoğlu was part of a EBAC-accredited symposium

Slides as educational service to PACE members and meeting participants.

Slides: Unravelling the triglyceride story

Slides (presentation) - Sep. 13, 2021 - Peter Libby, MD - Boston, MA, USA - CME symposium held during ESC Congress 2021
This lecture by Peter Libby was part of a EBAC-accredited symposium

Slides as educational service to PACE members and meeting participants.

Tackling residual risk beyond LDL-c therapy: The emerging role of EPA & triglycerides